IL265688A - A preparation containing a combination of a trh analog with arundic acid, and a pharmaceutically acceptable salt of arundic acid - Google Patents

A preparation containing a combination of a trh analog with arundic acid, and a pharmaceutically acceptable salt of arundic acid

Info

Publication number
IL265688A
IL265688A IL265688A IL26568819A IL265688A IL 265688 A IL265688 A IL 265688A IL 265688 A IL265688 A IL 265688A IL 26568819 A IL26568819 A IL 26568819A IL 265688 A IL265688 A IL 265688A
Authority
IL
Israel
Prior art keywords
arundic acid
composition
combination
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL265688A
Other languages
English (en)
Hebrew (he)
Original Assignee
Brivention Pharmaceutical Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brivention Pharmaceutical Shanghai Inc filed Critical Brivention Pharmaceutical Shanghai Inc
Publication of IL265688A publication Critical patent/IL265688A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/10Antiepileptics; Anticonvulsants for petit-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • C07C53/128Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/30Other Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL265688A 2016-10-03 2019-03-28 A preparation containing a combination of a trh analog with arundic acid, and a pharmaceutically acceptable salt of arundic acid IL265688A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016195505 2016-10-03
JP2017184731 2017-09-26
PCT/JP2017/034926 WO2018066427A1 (ja) 2016-10-03 2017-09-27 Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Publications (1)

Publication Number Publication Date
IL265688A true IL265688A (en) 2019-05-30

Family

ID=61832036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265688A IL265688A (en) 2016-10-03 2019-03-28 A preparation containing a combination of a trh analog with arundic acid, and a pharmaceutically acceptable salt of arundic acid

Country Status (16)

Country Link
US (1) US10828303B2 (enExample)
EP (1) EP3520795B1 (enExample)
JP (2) JP6596697B2 (enExample)
KR (1) KR20190065315A (enExample)
CN (2) CN113559102B (enExample)
AU (1) AU2017340594B2 (enExample)
BR (1) BR112019006429A2 (enExample)
CA (1) CA3039027A1 (enExample)
CO (1) CO2019003255A2 (enExample)
IL (1) IL265688A (enExample)
MX (1) MX2019003837A (enExample)
PH (1) PH12019500636A1 (enExample)
SG (1) SG11201902599SA (enExample)
TW (1) TW201818939A (enExample)
WO (1) WO2018066427A1 (enExample)
ZA (1) ZA201902341B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907591D0 (en) * 2019-05-29 2019-07-10 Eolas Res Limited Composition and use
IT202000015895A1 (it) 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6223429A (ja) * 1985-07-24 1987-01-31 Ishikawajima Harima Heavy Ind Co Ltd 水素同位体の回収・貯蔵・供給装置
JPS62234029A (ja) * 1985-12-27 1987-10-14 Tanabe Seiyaku Co Ltd 中枢神経賦活剤
TW248552B (enExample) 1993-06-01 1995-06-01 Onoda Yakuhin Kogyo Kk
JPH0782166A (ja) 1993-09-14 1995-03-28 Tanabe Seiyaku Co Ltd 抗ショック剤
US9016221B2 (en) * 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005105722A1 (ja) * 2004-04-28 2005-11-10 Ono Pharmaceutical Co., Ltd. (2r)−2−プロピルオクタン酸とアミンとからなる結晶
JP2006143708A (ja) * 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
TWI585071B (zh) * 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
PT2443120T (pt) * 2009-06-16 2017-02-08 Rspr Pharma Ab Forma cristalina de pemirolast
CN102786414B (zh) * 2012-08-15 2014-07-16 四川大学 一类用于治疗和/或预防神经退行性相关疾病的化合物

Also Published As

Publication number Publication date
NZ752311A (en) 2020-12-18
JP6596697B2 (ja) 2019-10-30
MX2019003837A (es) 2019-06-24
CN113559102A (zh) 2021-10-29
CO2019003255A2 (es) 2019-04-12
US20190240221A1 (en) 2019-08-08
CN113559102B (zh) 2023-01-03
KR20190065315A (ko) 2019-06-11
TW201818939A (zh) 2018-06-01
CA3039027A1 (en) 2018-04-12
ZA201902341B (en) 2020-08-26
CN110267661B (zh) 2021-08-03
JP2019203007A (ja) 2019-11-28
JPWO2018066427A1 (ja) 2019-07-25
EP3520795A1 (en) 2019-08-07
PH12019500636A1 (en) 2019-10-28
BR112019006429A2 (pt) 2019-06-25
AU2017340594A1 (en) 2019-04-18
US10828303B2 (en) 2020-11-10
SG11201902599SA (en) 2019-05-30
CN110267661A (zh) 2019-09-20
EP3520795B1 (en) 2023-06-14
EP3520795A4 (en) 2020-05-13
AU2017340594B2 (en) 2020-09-10
WO2018066427A1 (ja) 2018-04-12

Similar Documents

Publication Publication Date Title
ZA201707981B (en) Compositions of obeticholic acid and methods of use
IL251834B1 (en) Pharmaceutical compositions containing peptide variants and methods of using them
CA3244408A1 (en) Therapeutic compositions, combinations, and methods of use
IL253796A0 (en) Therapeutically active compounds and methods of use
IL251246A0 (en) Therapeutically active compounds and methods of use
EP3139935A4 (en) Therapeutic placental compositions, methods of making and methods of use
IL258922A (en) Methods for the preparation of obeticholic acid and derivatives thereof
EP3274472A4 (en) Antimicrobial peptides and methods of use thereof
PT3340973T (pt) Sais farmaceuticamente aceitáveis de ácido beta-guanidinopropiónico com propriedades melhoradas e seus usos
EP3288379A4 (en) Peptide compositions and methods of use
EP3265476A4 (en) Protoxin-ii variants and methods of use
PL3319609T3 (pl) Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych
EP3247365A4 (en) Novel iodophor composition and methods of use
EP3277304A4 (en) Protoxin-ii variants and methods of use
EP3313427A4 (en) Therapeutic peptides and methods of use thereof
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
SG10202008700VA (en) α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
IL262405A (en) Methods for preparing obeticholic acid and its derivatives
ZA201902341B (en) Composition comprising combination of trh analog with arundic acid, and pharmaceutically acceptable salt of arundic acid
SI3349594T1 (sl) Sestavek nadomestka soli in uporaba le-tega
PT3503885T (pt) Composição farmacêutica e métodos de utilização
IL254732A0 (en) In vitro preservation of therapeutic cells
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
TWI559918B (en) Use of gallic acid and its pharmaceutically acceptable salt
PL3341481T3 (pl) Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne